Deciding Between Active Surveillance and Targeted Therapy in BRCA+ Prostate Cancer

Video

Leonard G. Gomella, MD, discusses deciding between active surveillance and precision medicine in mutated prostate cancer.

Leonard G. Gomella, MD, the chair of the Department of Urology and director of the Sidney Kimmel Cancer Center Network at Thomas Jefferson University Hospital, discusses deciding between active surveillance of a patients with BRCA-mutated prostate cancer or treating with precision medicine approach.

According to Gomella, very few studies have been conducted that connect mutated disease to active surveillance. Patients with BRCA1/2 mutated prostate cancer are more likely to fall off of active surveillance. However, not a lot of guidelines exist when it comes to the subject.

Genetic alterations are integrated into surveillance decisions, according to Gomella. Genetic alterations in breast and ovarian cancer are more prevalent in women than men who develop prostate cancer. However, men who have a family history of breast or ovarian cancer should consider early prostate cancer screenings.

Related Videos
Video 8 - "Clinical Pearls for Optimal Management of mHSPC"
Video 7 - "Multidisciplinary Approach in mHSPC Management "
Video 6 - "Treatment Considerations in High Disease Burden and Comorbidities"
Video 5 - "Pivotal Trials in mHSPC"
Video 4 - "ARASENS Trial- Darolutamide in mHSPC"
Video 3 - "Treatment Intensification in Metastatic Prostate Cancer"
Video 2 - "Treatment Options for mHSPC"
Video 1 - "Initial Impression and Risk Assessment"
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Related Content